GlassScriptPhysician profile
Benjamin J Hyatt
NPI 1477518678
$135,043.81
in general payments reported to CMS, 2019-2025
38 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $273 · 2021: $230 · 2022: $5,123 · 2023: $14K · 2024: $46K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Consulting Fee: $17K · Food and Beverage: $13K · Travel and Lodging: $7,519 · Education: $62.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,854.36 |
| Consulting Fee | $16,887.50 |
| Food and Beverage | $13,219.66 |
| Travel and Lodging | $7,519.20 |
| Education | $62.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $114,849.15 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $5,539.27 | 2019-2025 | Entyvio, Eohilia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $3,684.09 | 2022 | |
| Abbvie INC. | $2,323.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,438.41 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Ardelyx, INC. | $1,427.46 | 2023-2025 | Ibsrela |
| Pfizer INC. | $991.80 | 2019-2025 | |
| Qol Medical, LLC | $874.40 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $586.17 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $520.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $336.72 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $322.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $259.06 | 2019-2025 | Rebyota |
| Genzyme Corporation | $245.52 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $235.14 | 2024-2025 | Voquezna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $210.11 | 2024-2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $198.02 | 2019-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $126.93 | 2024 | Stelara |
| Celltrion USA INC. | $102.95 | 2024-2025 | Zymfentra, Yuflyma, Vegzelma |
| Aimmune Therapeutics, INC. | $98.29 | 2024-2025 | Vowst |
| Fresenius Kabi USA, LLC | $89.40 | 2023-2024 | Idacio |
| Lilly USA, LLC | $74.22 | 2024-2025 | Omvoh, Zepbound |
| Stryker Corporation | $68.59 | 2024 | Neptune |
| Braintree Laboratories, INC. | $67.85 | 2019-2022 | |
| Neuraxis, INC. | $54.32 | 2025 | |
| Intercept Pharmaceuticals, INC. | $47.48 | 2024-2025 | |
| Micro-Tech Endoscopy USA, INC. | $33.27 | 2019-2025 | Lockado |
| Merck Sharp & Dohme LLC | $30.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2024 | Cyltezo |
| Boston Scientific Corporation | $29.96 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $25.61 | 2023 | Fujifilm |
| Ucb, INC. | $24.78 | 2019-2020 | |
| Organon LLC | $18.74 | 2024 | |
| Echosens North America, INC. | $18.46 | 2022 | |
| Sandoz INC. | $16.47 | 2023 | Hyrimoz |
| Medtronic, INC. | $14.92 | 2025 | Gi Genius |
| Capsovision, INC. | $14.44 | 2023 | Capsocam Plus |
| Allergan, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hyatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.